Gefitinib Hydrochloride置于碳,Sodium Hydroxide,乙腈体系中,用 水合甲醇 用作溶剂,化学反应 3.0H,以to Afford Crude Gefitinib As Off-White Solid (19.8 G) With 96.7% Purity的收率获得吉非替尼 参考文献:Process Of Preparing A Quinazoline Derivative 标题:Process Of Preparing A Quinazoline Derivative 摘要:一种简洁,高效,节约成本和时间的制备a式喹唑啉衍生物的方法如下:该方法是制备吉非替尼或吉非替尼中间体的方法之一,包括在一锅反应中,使用b式化合物,3-氯-4-氟苯胺(Vi),N,N-二烷基甲酰胺缩醛,布朗斯特酸催化剂和溶剂反应.
专利号:US-2024035023-A1 优先权日:2022-06-24 标题 :Computer implemented method for engineering fluorinase enzymes for synthesis of fluorophenyl compounds 发明人:R PRAVIN KUMAR; G GLADSTONE SIGAMANI; L ROOPA; B K NAVEEN; SHETTY ANUJ J; M LIKITH 权利人:KCAT ENZYMATIC PRIVATE LTD 摘要:The present invention discloses a computer-implemented method for engineering fluorinase enzymes towards the synthesis of fluorophenyl compounds. Limited or no mechanistic details of fluorinase enzymes have hindered progress in understanding their catalytic mechanisms for synthesizing synthetic organofluorine compounds. Through a comprehensive computational screening process, specific methionine-sulfonium phenyl substrates, including [(3S)-3-amino-3-carboxypropyl][2,5-difluoro-4-(4-methoxy-2,4-dioxobutyl)phenyl]methylsulfonium, were designed and optimized using quantum chemical optimization techniques. This methodology uncovers crucial information on F— ion attack conformation and the catalytic mechanism of the substrate, leading to the formation of Methyl 3-oxo-4-(2,4,5-trifluorophenyl)butanoate. Furthermore, a protein sequence and 3D modeling-based enzyme screening process was employed to identify the most suitable enzyme for this substrate. The identified enzyme was then engineered using the mechanistic insights gained from the studies, resulting in improved substrate scope, stability and catalytic efficiency. This computer-based approach offers an efficient and precise alternative to traditional trial-and-error methods, advancing the field towards the successful synthesis fluorophenyl compounds.
专利号:US-10973847-B2 优先权日:2017-06-30 标题 :Core-to-surface polymerization for the synthesis of star polymers and uses thereof 发明人:JOHNSON JEREMIAH A; GOLDER MATTHEW R 权利人:MASSACHUSETTS INST TECHNOLOGY 摘要:Disclosed are methods, compositions, reagents, systems, and kits to prepare star polymers, as well as compositions and uses thereof. Various embodiments show that synthesis of these polymers contain low metal concentration to provide polymers for diverse biomedical applications including in vivo applications.
专利号:US-11311505-B2 优先权日:2017-02-24 标 题:Synergistic compositions to stimulate the synthesis of human lung and sinus surfactants to decrease coughing, increase FEV-1/FVC ratios, decrease lung fibrosis, by increasing apoptosis of myofibroblasts 发明人:MARTIN ALAIN 权利人:MARTIN ALAIN; CELLULAR SCIENCES INC 摘要:Methods for the treatment of patients with both Chronic Obstructive Pulmonary Disease (COPD) and pulmonary fibrosis, and of patients with idiopathic pulmonary fibrosis without COPD, by stimulating the synthesis of human and animal patient lung and sinus surfactants to increase lung functions, inhibiting fibrosis and reducing coughing and nasal erythema, include the following steps: A) analyzing and diagnosing a patient with a lung ailment selected from the group consisting of i) both COPD and pulmonary fibrosis; and ii) idiopathic pulmonary fibrosis without COPD; and, B) treating the patient to raise the patient's lung functions including FEV1/FVC ratio by contacting mammalian cells with a [therapeutically effective amount of a treatment] composition that includes: a) a pyruvate salt; b) a phosphate; c) a salt of calcium; and d) a salt of magnesium, in an aqueous carrier, containing no more than 2.2 grams of said pyruvate salt per liter.
专利号:US-2024209029-A1 优先权日:2021-04-21 标题:Adiponectin glycopeptides and compositions and methods of use thereof 发明人:WANG YU; LI XUECHEN; XU AIMIN; WU HONGXIANG; ZHANG YIWEI; LI YUANXIN 权利人:UNIV HONG KONG 摘要:An improved method for the chemical synthesis of glycosylated peptides has been developed. The method uses stereoselective glycan synthesis and chemical peptide ligation to produce glycopeptides at lower-cost and with higher efficiency/yield compared to conventional methods. In particular, a method for the large-scale, chemical synthesis of hydroxylated amino acid building blocks and glycosylated amino acids suitable for solid phase peptide synthesis (SPPS) are disclosed. SPPS-based methods using the glycosylated amino acids to chemically synthesize adiponectin-like peptides are also described. In vivo studies show that the adiponectin mimicking glycopeptides exhibit significant anticancer, anti-obesity and insulin sensitizing effects. Pharmaceutical compositions of the synthetic glycopeptides and methods of use thereof in treating diseases associated with deficient adiponectin are also described.
专利号:US-12115231-B2 优先权日:2015-05-04 标题 :Ultrasmall nanoparticles and methods of making and using same 发明人:WIESNER ULRICH B; MA KAI; MENDOZA CARLIE 权利人:UNIV CORNELL 摘要:An aqueous synthesis methodology for the preparation of silica nanoparticles (SNPs), core-shell SNPs having, for example, a size of 2 to 15 nm and narrow size-dispersion with size control below 1 nm, i.e. at the level of a single atomic layer. Different types of dyes, including near infrared (NIR) emitters, can be covalently encapsulated within and brightness can be enhanced via addition of extra silica shells. The surface may be functionalized with polyethylene glycol (PEG) groups and, optionally, specific surface ligands. This aqueous synthesis methodology also enables synthesis of 2 to 15 nm sized fluorescent core and core-shell aluminosilicate nanoparticles (ASNPs) which may also be surface functionalized. Encapsulation efficiency and brightness of highly negatively charged NIR fluorophores is enhanced relative to the corresponding SNPs without aluminum.
专利号:US-2017283878-A1 优先权日:2015-12-11 标题:Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers 发明人:WONG CHI-HUEY; WU CHUNG-YI; CHEUNG SARAH K C; CHUANG PO-KAI; HSU TSUI-LING 权利人:ACADEMIA SINICA 摘要:The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for diagnostic and therapeutic uses.
1: Marech I, Vacca A, Gnoni A, Silvestris N, Lorusso V. Surgical resection of locally advanced epidermal growth factor receptor (EGFR) mutated lung adenocarcinoma after gefitinib and review of the literature. Tumori. 2013 Sep-Oct;99(5):e241-4. doi: 10.1700/1377.15324. Review. doi: 10.1371/journal.pone.0059314. Epub 2013 Mar 21. Review. 3: Biaoxue R, Shuanying Y, Wei L, Wei Z, Zongjuan M. Maintenance therapy of gefitinib for non-small-cell lung cancer after first-line chemotherapy regardless of epidermal growth factor receptor mutation: a review in Chinese patients. Curr Med Res Opin. 2012 Oct;28(10):1699-708. doi: 10.1185/03007995.2012.728525. Epub 2012 Oct 2. Review. Review. doi: 10.1159/000341528. Epub 2012 Aug 22. Review. doi: 10.5414/CP201759. Review. doi: 10.1016/j.clon.2011.09.013. Epub 2011 Oct 22. Review. doi: 10.1517/14740338.2011.617738. Epub 2011 Sep 12. Review. doi: 10.1155/2011/815269. Epub 2011 May 23. Review. 10: Gottschling S, Penzel R, Pelz T, Herpel E, Schnabel PA, Dyckhoff G, Thomas M, Kuhnt T. KRAS-mutation positive, metastatic tonsil carcinoma with cancer stem-like cell features and long-term response to gefitinib: a case report and review of the literature. J Clin Oncol. 2011 Jul 20;29(21):e616-9. doi: 10.1200/JCO.2011.34.5892. Epub 2011 May 9. Review.
合成参考文献
参考文献:10.1016/j.canlet.2010.01.028 摘要:Zhu H, Cao X, Ali-Osman F, Keir S, Lo HW. EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity. Cancer Lett. 2010 Aug 01;294(1):101–10. 摘要:Fujimoto H, Oyama T, Suito T, Hashimoto K, Kameyama Y, Yasuda H, Ishizuka H. [A case of complete response treated by S-1 with concurrent radiotherapy for a gefitinib-resistant non-small cell lung cancer patient]. Gan To Kagaku Ryoho. 2010 Feb;37(2):295–8. 参考文献:10.1007/s00432-010-0785-z 摘要:Jian G, Songwen Z, Ling Z, Qinfang D, Jie Z, Liang T, Caicun Z. Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology. 2010 Feb 14;136(9):1341–7. doi: 10.1007/s00432-010-0785-z. 参考文献:10.1016/j.oraloncology.2009.11.010 摘要:Bozec A, Formento P, Fischel JL, Etienne-Grimaldi MC, Milano G. Tapered dose versus constant drug exposure to anti-EGFR drugs on head-and-neck cancer xenografts. A comparison between cetuximab and gefitinib. Oral Oncol. 2010 Mar;46(3):172–7. doi: 10.1016/j.oraloncology.2009.11.010. 参考文献:10.1007/s12094-010-0473-0 摘要:Rosell R, Morán T, Carcereny E, Quiroga V, Molina MÁ, Costa C, Benlloch S, Tarón M. Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain. Clinical and Translational Oncology. 2010 Feb 20;12(2):75–80. doi: 10.1007/s12094-010-0473-0.